- Home
- BCSF vs SYRE Comparison
BCSF vs SYRE Comparison
Compare BCSF & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- SYRE
- Stock Information
- Founded
- BCSF 2015
- SYRE 2013
- Country
- BCSF United States
- SYRE United States
- Employees
- BCSF N/A
- SYRE N/A
- Industry
- BCSF Finance/Investors Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- SYRE Health Care
- Exchange
- BCSF Nasdaq
- SYRE Nasdaq
- Market Cap
- BCSF 901.0M
- SYRE 1.1B
- IPO Year
- BCSF 2018
- SYRE 2016
- Fundamental
- Price
- BCSF $13.94
- SYRE $22.85
- Analyst Decision
- BCSF Buy
- SYRE Strong Buy
- Analyst Count
- BCSF 2
- SYRE 5
- Target Price
- BCSF $16.50
- SYRE $55.75
- AVG Volume (30 Days)
- BCSF 378.7K
- SYRE 1.4M
- Earning Date
- BCSF 11-10-2025
- SYRE 11-06-2025
- Dividend Yield
- BCSF 12.88%
- SYRE N/A
- EPS Growth
- BCSF N/A
- SYRE N/A
- EPS
- BCSF 1.66
- SYRE N/A
- Revenue
- BCSF $283,687,000.00
- SYRE N/A
- Revenue This Year
- BCSF N/A
- SYRE N/A
- Revenue Next Year
- BCSF N/A
- SYRE N/A
- P/E Ratio
- BCSF $8.40
- SYRE N/A
- Revenue Growth
- BCSF N/A
- SYRE N/A
- 52 Week Low
- BCSF $13.20
- SYRE $10.91
- 52 Week High
- BCSF $19.21
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- BCSF 40.01
- SYRE 56.15
- Support Level
- BCSF $13.85
- SYRE $22.48
- Resistance Level
- BCSF $14.18
- SYRE $25.06
- Average True Range (ATR)
- BCSF 0.27
- SYRE 1.19
- MACD
- BCSF 0.01
- SYRE -0.22
- Stochastic Oscillator
- BCSF 25.00
- SYRE 21.26
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.